0.90USD
41.96 MUSD
674.98 MUSD
45.17 M
About Pacira BioSciences, Inc.
Sector
CEO
Frank D. Lee
Headquarters
Tampa
Website
Employees (FY)
712
Founded
2006
FIGI
BBG0018FQNS6
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PCRX is 25.99 USD — it has decreased by 3.06% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pacira BioSciences, Inc. stocks are traded under the ticker PCRX.
Pacira BioSciences, Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
PCRX stock is 4.00% volatile and has beta coefficient of 0.78. Check out the list of the most volatile stocks — is Pacira BioSciences, Inc. there?
PCRX earnings for the last quarter are 0.72 USD per share, whereas the estimation was 0.78 USD resulting in a −7.77% surprise. The estimated earnings for the next quarter are 0.88 USD per share. See more details about Pacira BioSciences, Inc. earnings.
Pacira BioSciences, Inc. revenue for the last quarter amounts to 163.93 M USD despite the estimated figure of 172.95 M USD. In the next quarter revenue is expected to reach 180.62 M USD.
Yes, you can track Pacira BioSciences, Inc. financials in yearly and quarterly reports right on TradingView.
PCRX stock has fallen by 3.81% compared to the previous week, the month change is a 9.98% fall, over the last year Pacira BioSciences, Inc. has showed a 42.85% decrease.
PCRX net income for the last quarter is 24.87 M USD, while the quarter before that showed 10.86 M USD of net income which accounts for 129.05% change. Track more Pacira BioSciences, Inc. financial stats to get the full picture.
Today Pacira BioSciences, Inc. has the market capitalization of 1.25 B, it has decreased by 2.87% over the last week.
No, PCRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PCRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pacira BioSciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 24, 2024, the company has 712.00 employees. See our rating of the largest employees — is Pacira BioSciences, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pacira BioSciences, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pacira BioSciences, Inc. stock shows the strong sell signal. See more of Pacira BioSciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Pacira BioSciences, Inc. future price: according to them, PCRX price has a max estimate of 57.00 USD and a min estimate of 36.00 USD. Read a more detailed Pacira BioSciences, Inc. forecast: see what analysts think of Pacira BioSciences, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pacira BioSciences, Inc. EBITDA is 162.90 M USD, and current EBITDA margin is 24.13%. See more stats in Pacira BioSciences, Inc. financial statements.